Loading...

FITC anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
rb6-8c5
C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C (clone RB6-8C5) FITC and CD11b PE.
  • rb6-8c5
    C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C (clone RB6-8C5) FITC and CD11b PE.
Compare all formats See FITC spectral data
Cat # Size Price Save
108405 50 µg ¥5,280
108406 500 µg ¥23,830
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Zhang J, et al. 2015. PLoS One. 10:130441. PubMed
  2. Montagner S, et al. 2016. Cell Rep. 15: 1566-1579. PubMed
  3. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  4. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  5. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  6. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  7. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  8. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  9. Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed
  10. Liu X, et al. 2022. Chin Med J (Engl). 135:1821. PubMed
  11. Xu Y, et al. 2023. EMBO Rep. 24:e55503. PubMed
  12. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  13. Meacham CE, et al. 2022. Nat Cell Biol. 24:697. PubMed
  14. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  15. Wu Q, et al. 2023. Front Immunol. 13:1081719. PubMed
  16. Lin CH, et al. 2023. iScience. 26:106904. PubMed
  17. Furuhashi K, et al. 2017. Immunology. 151:227. PubMed
  18. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
  19. Guan F, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0446-7. PubMed
  20. Kitur K, et al. 2016. Cell Rep. 16:2219-2230. PubMed
  21. Gazit R, et al. 2014. J Exp Med. 211:1315. PubMed
  22. Jackson A, et al. 2014. J Leukoc Biol. 92:609. PubMed
  23. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  24. Gan C, et al. 2022. Respir Res. 23:32. PubMed
  25. Jones NM, et al. 2019. BMC Cancer. 1.127777778. PubMed
  26. Morimura S, et al. 2013. Am J Pathol. 182:6140. PubMed
  27. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  28. Zhang Z, et al. 2020. J Immunol. 204:3400. PubMed
  29. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  30. Chen X, et al. 2021. Theranostics. 11:4655. PubMed
  31. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  32. Wang X, et al. 2016. PLoS Pathog. 12: 1005367. PubMed
  33. Al-Rifai R, et al. 2022. Nat Commun. 13:6592. PubMed
  34. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  35. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  36. Tilstam PV, et al. 2021. J Clin Invest. 131:. PubMed
  37. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  38. Martin R, et al. 2014. J Leukoc Biol. 96:151. PubMed
  39. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  40. Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed
  41. Herman KD, et al. 2022. Front Immunol. 13:956991. PubMed
  42. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  43. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  44. Karachi A, et al. 2019. Neuro Oncol. 1.381944444. PubMed
  45. Blijswijk J, et al. 2015. J Immunol. 194:307. PubMed
  46. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  47. Pawaria S, et al. 2020. Arthritis Rheumatol. 72:359. PubMed
  48. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  49. Cuff AO, et al. 2020. Frontiers in Immunology. 1.930555556. PubMed
  50. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  51. Wang C, et al. 2017. J Immunol. 10.4049/jimmunol.1700671. PubMed
  52. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  53. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  54. Fang R, et al. 2019. Mucosal Immunol. 12:1092. PubMed
  55. Piao W, et al. 2020. Cell Reports. 30(4):1052-1062.e5.. PubMed
  56. Qi X, et al. 2019. Nat Med. 25:1225. PubMed
  57. Suo J, et al. 2014. J Leukoc Biol. 96:133. PubMed
  58. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  59. Kakizaki M, et al. 2021. Cell Death Dis. 12:1010. PubMed
  60. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  61. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  62. Jaworska K, et al. 2015. J Immunol. 194:325. PubMed
  63. Shankar J 2016. Innate Immunity. 22: 31 - 39. PubMed
  64. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  65. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  66. Omori S, et al. 2021. Cell Reports. 34(6):108734. PubMed
  67. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  68. Morimura S, et al. 2021. Int J Mol Sci. :22. PubMed
  69. Dong S, et al. 2021. Nature. 591:117. PubMed
  70. Greenwald AC, et al. 2019. J Exp Med. 216:215. PubMed
  71. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  72. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  73. Nguyen GT, et al. 2021. iScience. 24(8):102871. PubMed
  74. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  75. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  76. Wang H, et al. 2022. J Nanobiotechnology. 20:445. PubMed
  77. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  78. Kren N, et al. 2020. Sci Rep. 10:7390. PubMed
  79. Bei T, et al. 2021. Molecules. 26:. PubMed
  80. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  81. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  82. Coquery C, et al. 2014. PLoS One. 9:102284. PubMed
  83. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  84. Wara AK, et al. 2020. Cell Rep. 33:108550. PubMed
  85. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  86. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  87. Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
  88. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  89. Zhai K, et al. 2021. Nat Cancer. 2:1136. PubMed
  90. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  91. Uderhardt S, et al. 2019. Cell. 177:541. PubMed
  92. Wang Q, et al. 2018. Int J Biol Sci. 14:147. PubMed
  93. Yamada D, et al. 2014. J Immunol. 192:4112. PubMed
  94. Ish-Shalom E, et al. 2016. J Immunol. 196: 156 - 167. PubMed
  95. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  96. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  97. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  98. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  99. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  100. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  101. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  102. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  103. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  104. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  105. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  106. Chen Z, et al. 2016. PLoS One. 11: 0146681. PubMed
  107. Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed
  108. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  109. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  110. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  111. Avalle L, et al. 2020. Mol Ther Methods Clin Dev. 0.793055556. PubMed
  112. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  113. Mesa-Nuñez C, et al. 2022. Mol Ther Methods Clin Dev. 26:459. PubMed
  114. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  115. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  116. DiMenna L, et al. 2010. J Immunol. 184:5475. PubMed
  117. Maulhardt HA, et al. 2020. Invest New Drugs. 1618:38. PubMed
  118. Gao P, et al. 2020. Front Immunol. 1.636111111. PubMed
  119. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  120. Chauhan P, et al. 2014. Int Immunopharmacol. 21:63. PubMed
  121. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  122. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  123. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  124. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  125. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  126. Saul S, et al. 2019. J Leukoc Biol. N/A. PubMed
  127. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  128. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  129. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  130. Maicas N, et al. 2017. PLoS One. 12(2):e0168981. PubMed
  131. An J, et al. 2015. Biochem Biophys Res Commun. 461:142. PubMed
  132. Morales J, et al. 2014. J Leukoc Biol. 95:643. PubMed
  133. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  134. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  135. Qu J, et al. 2021. Int J Biol Sci. 17:2756. PubMed
RRID
AB_313371 (BioLegend Cat. No. 108405)
AB_313371 (BioLegend Cat. No. 108406)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark PLUS UV395™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Red™ 718 anti-mouse Ly-6G/Ly-6C (Gr-1) (Flexi-Fluor™) RB6-8C5 FC
Spark Blue™ 574 anti-mouse Ly-6G/Ly-6C (Gr-1) (Flexi-Fluor™) RB6-8C5 FC
Go To Top Version: 2    Revision Date: 12/09/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account